Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:
“Proud to be a part of the final efficacy and safety report from the phase I/II ARROW trial of pralsetinib in RET fusion positive NSCLC published in Journal of Clinical Oncology.
As 1L therapy, RR 78%, mOS 50.1m. Post chemo RR 63%, mOS 39.7m. Now an approved, standard option.”
Title: Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
Authors: Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano, Daniel W. Bowles, Robert C. Doebele, Aaron S. Mansfield, Christina S. Baik, Gilberto de Lima Lopes, Luis Paz-Ares, Matthew H. Taylor, Daniel S. W. Tan, Guzman Alonso, Shirish M. Gadgeel, Gregory P. Kalemkerian, Sai-Hong Ignatius Ou, Anthonie J. van der Wekken, Carlos R. Becerra, Makenzi Evangelist, Frank Griesinger, Stephen V. Liu, Yanyan Lou, Julien Mazières, Jason M. Melear, Mohit Narang, Ashish Saxena, Michael Thomas, Sophia Wang, Amber Thomassen, Dae Ho Lee, Dong-Wan Kim, Justin F. Gainor
Other articles about NSCLC on OncoDaily.